Torrent Pharmaceuticals (Torrent Pharma) has signed a licensing agreement with Eli Lilly and Company with an objective to bring the latter’s baricitinib for Covid-19 treatment in India.
The royalty free, non-exclusive voluntary agreement enables Torrent Pharma to manufacture and distribute baricitinib along with Lilly’s other license partners.
According to Torrent Pharma, the agreement will help ensure a larger reach and access to Covid patients in India.
Baricitinib has been approved by India’s Central Drug Standard Control Organisation (CDSCO) for restricted emergency use in combination with remdesivir.
The combination is indicated for the treatment of suspected or lab confirmed Covid-19 in hospitalized adults who need supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Aman Mehta – Chief Marketing Officer for Torrent Pharma said: “We are pleased to partner and work closely with Lilly to bring this treatment to market. This partnership further strengthens our efforts to help the nation fight the pandemic and provide quality treatment to patients.
“Torrent Group stands firmly committed to support the nation during this time of crisis.”
Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib added by pallavi123 on
View all posts by pallavi123 →
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.